(BMEZ) BlackRock Health Sciences - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US09260E1055

BMEZ: Pharmaceuticals, Biotechnology, Medical Devices, Healthcare Services

Ticker Symbol: BMEZ | Exchange: NYSE | Type: Common Stock | Country Origin: United States | GICS Sub Industry: Health Care Services

Average Volume 20d: 349,964 | Last Price: 14.91 | SMA 20: 15.16 | SMA 50: 15.53 | SMA 200: 14.77 | ATR: 0.25

Market Cap: $1,529.96M USD | P/E: 71.95 | P/B: 0.92 | P/S: 62.06 | RoE: None

3-Month Forecast: Based on the moving averages, BMEZ is trading below its SMA 20 and SMA 50, signaling a bearish trend. However, the SMA 200 is slightly below the current price, suggesting potential support. The low ATR of 0.25 indicates reduced volatility. With a forward P/E of 0.00, the stock may face uncertainty. Expect sideways movement with potential upside if the price breaks above the SMA 50.

Additional Sources for BMEZ Stock

BMEZ Stock Overview

Market Cap in USD 1,447m
GiC Sub-Industry Health Care Services
IPO / Inception 2020-01-29

BMEZ Stock Ratings

Growth Rating 7.22
Fundamental -
Dividend Rating 90.4
Rel. Strength 14.4
Analysts -
Fair Price Momentum 15.20 USD
Fair Price DCF 18.86 USD

BMEZ Dividends

Dividend Yield 12m 13.98%
Yield on Cost 5y 16.51%
Annual Growth 5y 13.43%
Payout Consistency 97.7%

BMEZ Growth Ratios

Growth Correlation 3m -92.4%
Growth Correlation 12m 59%
Growth Correlation 5y -34.3%
CAGR 5y 3.46%
CAGR/Max DD 5y 0.08
Sharpe Ratio 12m 0.20
Alpha 3.99
Beta 0.541
Volatility 27.66%
Current Volume 332.5k
Average Volume 20d 323.2k
What is the price of BMEZ stocks?
As of May 02, 2025, the stock is trading at USD 14.61 with a total of 332,488 shares traded.
Over the past week, the price has changed by +3.99%, over one month by +1.31%, over three months by -7.56% and over the past year by +12.97%.
Is BlackRock Health Sciences a good stock to buy?
Neither. Based on ValueRay Analyses, BlackRock Health Sciences is currently (May 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 7.22 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BMEZ as of May 2025 is 15.20. This means that BMEZ is currently overvalued and has a potential downside of 4.04%.
Is BMEZ a buy, sell or hold?
BlackRock Health Sciences has no consensus analysts rating.
What are the forecast for BMEZ stock price target?
According to ValueRays Forecast Model, BMEZ BlackRock Health Sciences will be worth about 17 in May 2026. The stock is currently trading at 14.61. This means that the stock has a potential upside of +16.36%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 17 16.4%